Farmacosmo S p A : “Farmacosmo Warrants 2022-2025” Exercise Period Results

PRESS RELEASE

"FARMACOSMO WARRANTS 2022-2025"

EXERCISE PERIOD RESULTS

Naples, January 31st, 2023

Farmacosmo S.p.A. ("Company". "Farmacosmo"), a company active in the Health, Pharma & Beauty sector, listed on the Euronext Growth Milan market of Borsa Italiana, announces that on today's day, the First "FARMACOSMO WARRANTS 2022-2025" Exercised Period (hereinafter, "Warrant") between 15th January 2023 and 31st January 2021 (including initial and final terms) has ended.

During that period no Warrants have been presented to be exercised, and consequently no newly-issued ordinary shares of Farmacosmo S.p.A. have been subscribed.

Therefore, as a result of the above, at the current date there are still n. 1,022,218 Warrants in circulation, corresponding to all the securities issued at the time of the IPO, which may be exercised during the Second Exercise Period, between 15th January 2024 and 31st January 2024 (inclusive) and the Third Exercise Period, between 15th January 2025 and 31st January 2025 (inclusive), as required by the Warrant Regulation.

***

This press release is available on the www.farmacosmoinvestors.comwebsite, section "Investors/Press Releases" and on the authorized storage mechanism "eMarket Storage" (www.emarketstorage.com).

***

THE SOCIETY

Farmacosmo is a company active in the Health, Pharma & Beauty sectors. The company's business model is based on the circular model of the l(ea)n strategy, and is divided into three main business areas: Logistics, Intelligence and Node. Logistics: enables the management and fulfilment of up to 12,000 orders per day, with delivery times of up to 20 hours from carrier picking and just-intime procurement ('zero warehouse' policy). Intelligence: includes strategy definition, competitive positioning and customer journey activities, which enabled the company to intercept c. 188,000 customers in 2021. Recurring customers contributed 74% of the annual retail stream turnover. The average cart value of active customers in the retail stream amounted to €92 (€109 related to recurring customers). Node: R&D activities, process innovation and IT infrastructure of the company. Over the past five years, Farmacosmo's sales value has grown by 54% (CAGR 2016-2021) and will be around €58 million in 2021. The Farmacosmo ecosystem aims to pursue standards of excellence in every part of its value chain, being inspired by compliance with ESG principles at all stages of the logistics process (from the packaging used for online orders to carbon compensation initiatives) and in the valorisation of its employees, the company's strategic asset. Farmacosmo's commitment to ESG is also underlined by the publication of its Sustainability Report 2021.

IDENTIFICATION CODES

Ordinary Shares: ISIN IT0005487670 (Ticker COSMO)

Warrant Farmacosmo 2022-2025: ISIN IT0005487415 (Ticker WCOSMO)

FOR FURTHER INFORMATION:
INVESTOR RELATIONS MANAGER	EURONEXT GROWTH ADVISOR	INVESTOR & MEDIA RELATIONS ADVISOR
Farmacosmo	Illimity Bank	IR Top Consulting
Via Crispi, 51 - 80121 Naples	Via Soperga, 9 - 20124 Milan	Via Bigli, 19 - 20121 Milan
Tel. [phone]	Tel. [phone]	Tel. [phone]
Paolo [e-mail]	[e-mail]	Pietro Autelitano [e-mail]
		Domenico [e-mail]